Bookmark and Share








Salvia on Schedule: Detriment to Research
20 JULY 2009 - Scientific American

By David Jay Brown
From: Scientific American Magazine

As the source of the most powerful natural hallucinogen known, salvia is drawing scrutiny from U.S. authorities who want to restrict this Mexican herb, now used recreation­ally by some. But neuro­scientists worry that controlling it before studies have determined its safety profile is premature and could hamper research of the drug's medicinal value. Increasingly, evidence is piling up that it could lead to new and safer anti­depressants and pain relievers, as well as even help in improving treatments for such mental illnesses as schizophrenia and addiction.

The plant, formally known as Salvia divinorum, has a long tradition of shamanic usage by the Mazatec people of central Mexico. Salvinorin A, the primary psychoactive component, is part of a class of naturally occurring organic chemicals called diterpenoids, and it affects neural receptors in the brain similar to those that respond to opiate painkillers such as morphine—but without euphoric and addictive properties. That is because salvinorin A binds mostly to only one type of receptor (the so-called kappa opioid receptor) and not significantly to receptors that could lead to addiction (such as the mu opioid receptor).

As the popularity of salvia has risen over the past 16 years—its psychoactive properties were discovered in 1993 by Daniel Siebert, an independent ethnobotanist based in Malibu, CA—calls to treat the plant as an illegal drug have grown louder. Twelve states have recently placed S. divinorum in their most restrictive controlled substance category, and four others have laws restricting sales. The U.S. Drug Enforcement Administration has listed salvia as “a drug of concern” and is looking into the drug to determine whether it should be declared a Schedule I controlled substance, on par with heroin and LSD.

The unusual properties of salvinorin A intrigue scientists. Psychiatric researcher Bruce Cohen and his colleagues at Harvard Medical School have been developing analogues of salvinorin A and studying their possible mood-modulating properties. The team’s work with salvinorin A in animals suggests “that a drug that would block kappa opioid receptors might be an antidepressant drug—probably a nonaddictive one—or a mood stabilizer for patients with bipolar disorder,” Cohen remarks. By activating the kappa opioid receptors, drugs such as salvinorin A could reduce dependence on stimulants and the mood-elevating and mood-rewarding effects of cocaine. Because salvinorin A can produce distortions of thinking and perception, researchers speculate that blocking the receptors might alleviate some symptoms of psychoses and dissociative disorders.

Some investigators, including the team at Harvard, believe that modified forms of salvinorin A could bolster its medicinal value. Tom Prisinzano, a medicinal chemist at the University of Kansas, points out that some chemical transformations of salvinorin A have different pharmacological abilities—such as a longer-lasting action or an enhanced ability to bind to receptors—and no hallucinogenic properties. Modifying its novel structure, he says, “could potentially treat a number of different central nervous system disorders.”

But if salvinorin A becomes a federally scheduled drug, research on it would become “much more difficult,” predicts Rick Doblin, director of the Multidisciplinary Association for Psychedelic Studies, a nonprofit based in Santa Cruz, ­Calif. Prisinzano agrees, saying that “there will be a lot more paperwork involved,” subsequently making approval for clinical studies harder to obtain. For example, human studies with LSD were essentially blocked for more than 35 years because of federal restrictions, and currently only one human study with LSD is being conducted in the world. As Doblin puts it, approval boards at universities and research institutions view proposals involving criminalized drugs with extreme caution. “And funders are reluctant to look at potentially beneficial uses of drugs of abuse,” he adds.

Right now only two labs conduct human studies with salvinorin A: one run by psychiatric researchers Deepak Cyril D’Souza and Mohini Ranganathan, both at the Yale University School of Medicine, and the other by pharmacologist John Mendelson of the University of California, San Francisco. Both groups are performing preliminary tests to determine how best to administer salvinorin A to human volunteers and collect basic data. D’Souza and Ranganathan argue that scheduling the drug should wait until evidence about its effects and toxicity become clear.

The neuroscience community has yet to throw its collective weight behind formal battles against legal restrictions. “This has been more of a simmering back-burner than a flaming front-burner issue. Still, the issue is a serious one, with implications for policy, drug enforcement and research,” Cohen says. Many people have begun letter-writing campaigns to their representatives in Washington, D.C. Scientists as much as salvia fans undoubtedly hope that such grassroots activity could eventually alter the government’s mind.

The first comment to this article on Scientific American was from Randy S. Baker MD, who said; "Excellent article.  As a medical doctor, I find it disappointing and frustrating that scheduling has inhibited research on substances such as psilocybin and LSD, which have been shown by prior research to have tremendous therapeutic potential.  I hope there will be a more intelligent approach to dealing with salvia.  The argument that "scheduling the drug should wait until evidence about its effects and toxicity become clear" makes a lot of sense to me, but will it make sense to the DEA?"

Note: This article was originally printed with the title, "Salvia On Schedule."

Related Articles :
  • Annual Causes of Death in America ()
    The REAL truth is the most sobering statistic.
  • Extracting Salvinorin from Salvia Divinorum ()
    This is a concise extraction method for educational purposes only.
  • Traditional Quid Preparation ()
    Information regarding the traditional praparation of Salvia divinorum for divination by the Mazatecs.
  • Solubility of Active Components – Quick Guide ()
    Brief discussion on active components of plants and whether they were traditionally extracted into alcohol, water, or other solvents.
  • Salvia Divinorum Creates Catch-22 (12 March 12 2008)
    Florida follows the lead of eight other states and considers ban on Salvia divinorum.
  • Salvia divinorum - Diviner's Sage ()
    Salvia divinorum is a perennial labiate used for curing and divination by the Mazatec Indians of Oaxaca, Mexico. The psychotropic effects the plant produces are compared to those of the other hallucinogens employed by the Mazatecs, the morning glory, Rivea corymbosa L., Hallier F. and the psilocybin-containing mushrooms. A discussion of the role of ska María Pastora in the "native pharmacopoeia" is based on previous reports and fieldwork by the authors with a Mazatec shaman.
  • Studies of Salvia divinorum (Lamiaceae), ()
    Salvia divinorum Epling & Játiva-M. is one of the vision-inducing plants used by the Mazatec Indians of central Mexico. The present status of research is summarized.
  • Lessons in The Use of Mazatec Psychoactive Plants ()
    During the mid-1980’s I participated in a caving expedition in the Sierra Mazateca of Oaxaca, Mexico. Our group intended to explore and map the lower reaches of the Sotano de San Agustin, which at that time was the deepest known vertical cave in the western hemisphere.
  • Salvia Divinorum Cultivation: The Easy Way ()
    Growing her in itself is a magical experience. Yet there is probably no other plant that instills such an utter fear in beginner cultivators. When I went to bring her home from the greenhouse I bought her at, I almost expected to see her in some specially controlled atmospheric chamber with tubes and misting nozzles everywhere, and the dull whine of compressors and life support systems. Instead I was handed this tough looking little plant with a thick stem and yellowish green leaves that was sitting on the table by the door of the greenhouse. In awe of this little plant I brought her home and started to grow her.
  • Salvia Divinorum: Old Psychedelic Drug, New Appeal (April 28, 2008)
    The hallucinogenic herb Salvia divinorum can be purchased online or at a local head shop. While the DEA and others want to limit its use, scientists say making it a controlled substance would hinder research.
  • Brain's Reaction To Potent Hallucinogen Salvia Explored (April 28, 2008)
    U.S. Department of Energy is conducting new brain-imaging studies on animals, documenting the effects of Salvia divinorum on the brain.
  • Ethnopharmacology of Ska María Pastora ()
    S. divinorum is one of several vision-inducing plants employed by the Mazatec Indians, one of the native peoples living in the mountains and upland valleys of northeastern Oaxaca. Unlike other Mexican tribes, there is little information concerning their existence before the arrival of the conquering Spanish, who reduced the Mazatecan population through exploitation and disease.
Email This Article To A Friend - Print This Article
Articles can be E-mailed to a friend and you can get a printable version of the article
IMPORTANT: We provide all information for educational purposes only, and endorse or recommend nothing here.
A special thanks to Keith for all his support and insight.
Search Content :